News & Updates

2024 HK data on migraine in women

10 Sep 2024

A recent cross-sectional study in Hong Kong provides insights into lifestyle factors associated with migraine in women.

2024 HK data on migraine in women

10 Sep 2024

SGLT2i as 1L therapy for CKD: How to optimize real-world prescription?

29 Aug 2024 by

Kidney Disease: Improving Global Outcomes (KDIGO) 2024 clinical practice guideline recommends sodium-glucose cotransporter 2 inhibitors (SGLT2i) as first-line (1L) therapy for most patients with chronic kidney disease (CKD), with or without diabetes. Despite the established cardiorenal benefits of SGLT2i, prescription remains suboptimal in real-world CKD populations. At Advances in Medicine (AIM) 2024, Professor Jennifer Green of Duke University Medical Center in Durham, North Carolina, US, discussed empagliflozin’s cardiorenal benefits in broad CKD populations and the importance of early initiation of SGLT2i therapy in delaying CKD progression, while Dr Jack Ng of the Chinese University of Hong Kong presented strategies for optimizing SGLT2i prescription in CKD.

SGLT2i as 1L therapy for CKD: How to optimize real-world prescription?

29 Aug 2024

Use of an amyloid β–directed antibody in Alzheimer’s disease

29 Aug 2024 by

A 72-year-old male retired university lecturer with no family history of memory issues recently exhibited signs of memory decline, as observed by his family. The patient did not perceive any significant memory issues in himself and did not view himself as forgetful. He acknowledged that he may not remember things if he lacked interest in them or could not connect them to something familiar.

Use of an amyloid β–directed antibody in Alzheimer’s disease

29 Aug 2024

Nirmatrelvir/ritonavir reduces risk of severe COVID-19 in outpatients, regardless of vaccination status

28 Aug 2024

Nirmatrelvir/ritonavir is effective against the composite outcome of hospitalization or mortality ≤35 days after COVID-19 diagnosis in nonhospitalized adults with COVID-19, regardless of vaccination status, according to a systematic review and meta-analysis of cohort studies.

Nirmatrelvir/ritonavir reduces risk of severe COVID-19 in outpatients, regardless of vaccination status

28 Aug 2024

Clinical role of oral bempedoic acid in LDL-C management

28 Aug 2024 by

LDL-cholesterol (LDL-C) reduction is the key to preventing and treating atherosclerotic cardiovascular disease (ASCVD). Recent guidelines advocate aggressive LDL-C lowering in individuals at high or very high cardiovascular (CV) risk. At the Advances in Medicine 2024 conference, Dr Chu-Pak Lau, Specialist in Cardiology, discussed the clinical role of non-statin lipid-lowering therapies (LLTs), including oral bempedoic acid as a single agent or in fixed-dose combination (FDC) with ezetimibe, in patients who have failed to achieve guideline-recommended LDL-C targets or have statin intolerance.

Clinical role of oral bempedoic acid in LDL-C management

28 Aug 2024

GLP-1 RAs offer CV benefits in T2DM

28 Aug 2024 by

Cardiovascular (CV) benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) support their use in type 2 diabetes mellitus (T2DM). At a Novo Nordisk–sponsored lecture during the 6^th Annual Meeting of Endocrinology, Diabetes and Metabolism Hong Kong (EDM HK), Dr Julie Lovshin of the Division of Endocrinology and Metabolism, University of Toronto, Canada, reviewed clinical trials and real-world evidence on CV benefits provided by GLP-1 RAs, such as semaglutide, which led to guideline recommendations on their use in T2DM. Safety concerns related to GLP-1 RAs were also addressed.

GLP-1 RAs offer CV benefits in T2DM

28 Aug 2024

[Infographics] Don’t stop at HF: Screen for ATTR-CM

28 Aug 2024

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure (HF), affecting 1 in 10 patients with preserved left ventricular ejection fraction. Read this infographic to learn how to screen for ATTR-CM in HF patients and understand the survival benefits of early tafamidis treatment.

[Infographics] Don’t stop at HF: Screen for ATTR-CM

28 Aug 2024

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

28 Aug 2024 by

A 42-year-old male was hospitalized with a 2-week history of persistent fever, generalized maculopapular rash, and right cervical lymphadenopathy. His medical history and family history were unremarkable.

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

28 Aug 2024

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

28 Aug 2024 by

A 45-year-old male presented with generalized urticaria in September 2020. He had no past history of allergies, but had transient autoimmune thyroiditis in 2018, which subsequently resolved.

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

28 Aug 2024

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD

28 Aug 2024 by

A 55-year-old male with end-stage renal disease (ESRD) started peritoneal dialysis (PD) in January 2020, with a regimen of nocturnal automated PD with 2 L of 1.5 percent dextrose six shifts per night and 2 L of 7.5 percent icodextrin during the day.

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD

28 Aug 2024

News & Updates

Filter by Specialty:

Specialty:

2024 HK data on migraine in women

2024 HK data on migraine in women

SGLT2i as 1L therapy for CKD: How to optimize real-world prescription?

SGLT2i as 1L therapy for CKD: How to optimize real-world prescription?

Use of an amyloid β–directed antibody in Alzheimer’s disease

Use of an amyloid β–directed antibody in Alzheimer’s disease

Nirmatrelvir/ritonavir reduces risk of severe COVID-19 in outpatients, regardless of vaccination status

Nirmatrelvir/ritonavir reduces risk of severe COVID-19 in outpatients, regardless of vaccination status

Clinical role of oral bempedoic acid in LDL-C management

Clinical role of oral bempedoic acid in LDL-C management

GLP-1 RAs offer CV benefits in T2DM

GLP-1 RAs offer CV benefits in T2DM

[Infographics] Don’t stop at HF: Screen for ATTR-CM

[Infographics] Don’t stop at HF: Screen for ATTR-CM

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

Use of a C5 inhibitor in a patient with AOSD complicated by atypical haemolytic uraemic syndrome

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD

Addressing hyperphosphataemia with a polymer-based phosphate binder in a patient with ESRD